track margin expand rais po
 rais po
ticker grew revenu y/i revenu growth
set revenu growth expect y/i revenu
growth would argu tail wind vs
doubl manufactur capac mid-year
enter favor payer contract turn big consum
advertis campaign mid-year mostli us ou launch medicar
price headwind roughli revenu show upsid
fulli launch margin rapidli expand data come new
market think stock continu outperform reiter buy rate
rais po rev rev new po
base conserv revenu estim assum trade roughli line
despit dxcm faster revenu growth larger address market
call new
alreadi pre-announc revenu provid revenu guidanc
januari increment updat call posit
expect gross margin expans despit
price pressur expect oper margin expans
like prove quit conserv revenu upsid materi dxcm
oper margin came vs origin guid could well
achiev oper margin goal year earli view
also re-affirmed timelin full launch disclos end
year global patient announc plan build new manufactur
facil somewher outsid us manufactur like
see detail trial potenti new libr trial trial well
underway sinc requir post trial govern clinic trial
websit studi readi publish
full definit iqmethod sm measur see page
bofa secur seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
dexcom inc oper medic devic
compani focus design develop
continu glucos monitor cgm system
peopl diabet compani
develop small implant devic
continu measur glucos level
subcutan tissu skin real-tim
data process display patient
also alert level high low
product market physician
endocrinologist diabet educ
see sever avenu beat street
estim near term long-term penetr
non-intens type patient popul
increas total avail market opportun
also believ cgm remain top-tier
growth market patient adopt cgm
beneficiari tailwind
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
valu ev/sal given compani trade revenu growth
price object base revenu estim multipl line
high growth diabet compani revenu growth market opportun
least big
upsid risk strateg activ patient expect less impact
expect competit faster approv pipelin product
downsid risk price pressur fewer patient added/high attrit current
patient due competitor threat lack patient want adopt cgm delay
pipelin products/new market
travi steed herebi certifi view express research report accur
reflect person view subject secur issuer also certifi
part compens directli indirectli relat specif
recommend view express research report
becton dickinson compani
qualiti earn
iqmethod smi set bofa global research standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa global research
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
